New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
12:39 EDTCGENCompugen jumps after announcing newly discovered proteins
Compugen (CGEN) is rallying after the company announced earlier today that it has extended discovery capabilities to additional immunomodulatory proteins. WHAT'S NOTABLE: Compugen announced the extension of its predictive discovery capability to identify immunomodulatory proteins in addition to the B7/CD28-like proteins that have been the focus of the company’s pipeline program to date. The initial utilization of this extended capability resulted in the discovery of four novel immunomodulatory proteins predicted to act as immune checkpoints. The newly discovered proteins have been added to the company’s pipeline program as potential targets for cancer immunotherapy. Dr. Cohen-Dayag, CEO of Compugen, noted "We are of course very proud that in less than four years, we have established a growing position in this field, including a substantial early-stage pipeline of therapeutic product candidates for both oncology and immunology, based largely on our B7/CD28-like protein candidate discoveries. With today’s announcement, we are further broadening our early-stage pipeline with additional immunomodulatory opportunities and again demonstrating the power and flexibility of our predictive discovery capabilities." PRICE ACTION: In afternoon trading, Compugen 's stock rallied 51c, or almost 6%, to $9.39.
News For CGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
14:03 EDTCGENCompugen achieves second preclinical milestone under Bayer cancer collaboration
Compugen (CGEN) disclosed that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced relates to the second preclinical milestone for one of the checkpoint protein candidates.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use